Interní Med. 2016; 18(1): 38-42 | DOI: 10.36290/int.2016.010

Fulminant myocarditis

MUDr. Marcela Vránová
Interní oddělení, SMN a. s., Nemocnice Prostějov

Myocarditis is a disease characterized by inflammatory infiltrate with myocardial necrosis or degeneration of adjacent myocytes. It has a number of infectious and non-infectious causes. The most common cause of inflammatory diseases of the myocardium is a viral infection. May have non-fulminant or fulminant course – from asymptomatic or moderate disease course, to the most serious forms of manifesting severe heart failure or sudden death. Dilated cardiomyopathy that occur in connection with myocarditis is called inflammatory cardiomyopathy (ZKMP). In our case report, we discuss a rare form of fulminant myocarditis with fatal course.

Keywords: myokarditis, endomyocardial biopsy, fulminant myocarditis

Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vránová M. Fulminant myocarditis. Interní Med. 2016;18(1):38-42. doi: 10.36290/int.2016.010.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Feldman AM, et al. Myocarditis. N Engl J Med 200; 343: 1388-1398. Go to original source...
    2. Magnani JW, et al. Myocarditis: current trends in diagnosis and treatment. Circulation 2006; 111: 876-890. Go to original source...
    3. McCarthy RE III, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342: 690-695 Go to original source...
    4. Hufnagel G, et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First Epidemiological results. Herz 200; 25: 279-285.
    5. Vítovec J, Lipoldová J. Myokarditidy: Lék Listy 2007; 16: 10-11.
    6. Hare JM, Baughman KL. Fulminant and acute myocarditis: the prognostic value of clinicopathological classification. Hotline editoral. Eur Heart J 2001; 22: 269-270. Go to original source... Go to PubMed...
    7. Kuchynka P, Palecek T, Šimek S, et al. Komplexní bioptická diagnostika zánětlivé kardiomyopatie jako příčiny nově vzniklého srdečního selhání nejasné etiologie: první zkušenosti. Cor Vasa 2009; 51: 572-577. Go to original source...
    8. Kuchynka P, Palecek T, et al. Myokarditidy a zánětlivé kardiomyopatie. Kap Kardiol 2013; 5: 87-91.
    9. Gupta S, et al. Fulminant myocarditis. J of Cardio Med 2008; 5(11): 693-706. Go to original source...
    10. Cooper LT, jr. Myocarditis. N Engl J Med 2009; 360: 1526-1538. Go to original source...
    11. Felker GM, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 2000; 36: 227-232. Go to original source...
    12. Hiramitsu S, et al. Transient ventricular wall thickening in acute myocarditis: a serial echocardiographic and histopathologic study. Jpn Circ J 2001; 65: 863-866. Go to original source... Go to PubMed...
    13. De Cobelli F, Pieroni M, Esposito A, et al. Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol 2006; 45: 1815. Go to original source...
    14. Cooper LT, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007; 116: 2216-2233. Go to original source...
    15. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppresive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001; 104: 39-45. Go to original source...
    16. Robinson JL, et al. A systematic review of intraenous gamma globulin for therapy of acute myocarditis. BMC Cardiovasc. Disord 2005; 5: 12. Go to original source... Go to PubMed...
    17. McNamara DM, Holubkov R, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103: 2254. Go to original source...
    18. Gullestad L, Aass H, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103: 220. Go to original source...
    19. Palecek T, Kuchynka P, Hulinska D, et al. Presence of Borrelia burgdorferi in endomyocardial biopsies in patients with new-onset unexplained dilated cardimyopathy. Med Microbiol Immunol 2010; 199: 139-143. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.